Tissue Therapies patent accepted in Australia
Tuesday, 31 May, 2005
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
The acceptance follows the granting of the core VitroGro patent in New Zealand in March, the first jurisdiction to do so.
Tissue Therapies has worldwide exclusive rights to commercialise VitroGro under an IP Agreement with the Queensland University of Technology, and will also seek core patents for VitroGro in other jurisdictions such as the USA, Canada, Europe, South Korea, China and Japan.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...